|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Pluristem Therapeutics (PSTI) Announces Closing of Underwriters' Option to Purchase Additional Common Stock
9/24/2012 9:27:13 AM
HAIFA, Israel, Sept. 24, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), today announced the closing of the exercise in full of the underwriters' option to purchase an additional 1,200,000 shares of common stock of the company. As previously announced, as part of the firm commitment underwritten public offering that was closed on September 19, 2012, the company granted the underwriters a 30-day option to purchase up to 1,200,000 shares of common stock and/or warrants to purchase up to 420,000 shares of common stock. The underwriters previously exercised their option to purchase 1,200,000 warrants to purchase up to 420,000 of the company's common stock at an exercise price of $5.00 per share, at a purchase price of $0.0094 per warrant and have now also exercised their option to purchase 1,200,000 shares of common stock at $3.7506 per share. The gross proceeds to the company as a result of the exercise of this option are approximately $4.5 million.
|
|
|
|
|
|
|
|
|
|
|